Literature DB >> 18727707

Benzofuran derivatives and the thyroid.

T S Han1, G R Williams, M P J Vanderpump.   

Abstract

Amiodarone and dronedarone are two clinically important benzofuran derivatives. Amiodarone has been used widely for treating resistant tachyarrhythmias in the past three decades. However amiodarone and its main metabolically active metabolite desethylamiodarone can adversely affect many organs, including the thyroid gland. Amiodarone-induced thyroid disorders are common and often present as a management challenge for endocrinologists. The pathogenesis of amiodarone-induced thyroid dysfunction is complex but the inherent effects of the drug itself as well as its high iodine content appear to play a central role. The non-iodinated dronedarone also exhibits anti-arrhythmic properties but appears to be less toxic to the thyroid. This review describes the biochemistry of benzofuran derivatives, including their pharmacology and the physiology necessary for understanding the cellular mechanisms involved in their actions. The known effects of these compounds on thyroid action are described. Recommendations for management of amiodarone-induced hypothyroidism and thyrotoxicosis are suggested. Dronedarone appears to be an alternative but less-effective anti-arrhythmic agent and it does not have adverse effects on thyroid function. It may have a future role as an alternative agent in patients being considered for amiodarone therapy especially those at high risk of developing thyroid dysfunction but not in severe heart failure.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18727707     DOI: 10.1111/j.1365-2265.2008.03350.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

1.  Thyroid gland: use of glucocorticoids in amiodarone-induced thyrotoxicosis.

Authors:  Mark P J Vanderpump
Journal:  Nat Rev Endocrinol       Date:  2009-12       Impact factor: 43.330

2.  2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.

Authors:  Luigi Bartalena; Fausto Bogazzi; Luca Chiovato; Alicja Hubalewska-Dydejczyk; Thera P Links; Mark Vanderpump
Journal:  Eur Thyroid J       Date:  2018-02-14

3.  Endoplasmic reticulum stress as a novel mechanism in amiodarone-induced destructive thyroiditis.

Authors:  Angela Lombardi; William Barlow Inabnet; Randall Owen; Kaitlyn Ellen Farenholtz; Yaron Tomer
Journal:  J Clin Endocrinol Metab       Date:  2015-01       Impact factor: 5.958

Review 4.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

Review 5.  Effects of amiodarone therapy on thyroid function.

Authors:  Janna Cohen-Lehman; Peter Dahl; Sara Danzi; Irwin Klein
Journal:  Nat Rev Endocrinol       Date:  2010-01       Impact factor: 43.330

6.  Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study.

Authors:  Chun-Jui Huang; Po-Ju Chen; Jing-Wen Chang; De-Feng Huang; Shih-Lin Chang; Shih-Ann Chen; Tjin-Shing Jap; Liang-Yu Lin
Journal:  Int J Clin Pharm       Date:  2014-02-11

Review 7.  Dronedarone-current status in management of atrial fibrillation.

Authors:  Gajendra Manakshe; B Hygriv Rao
Journal:  Indian Heart J       Date:  2012-04-28

Review 8.  Adverse reactions of Amiodarone.

Authors:  Ruben Ml Colunga Biancatelli; Viviana Congedo; Leonardo Calvosa; Marco Ciacciarelli; Alessandro Polidoro; Luigi Iuliano
Journal:  J Geriatr Cardiol       Date:  2019-07       Impact factor: 3.327

Review 9.  Dronedarone for atrial fibrillation: a new therapeutic agent.

Authors:  Pawan D Patel; Rohit Bhuriya; Dipal D Patel; Bhaskar L Arora; Param P Singh; Rohit R Arora
Journal:  Vasc Health Risk Manag       Date:  2009-08-06

Review 10.  Dronedarone in the management of atrial fibrillation.

Authors:  Ts Mohamed Saleem; K Bharani; C Madhusudhana Chetty; K Gauthaman
Journal:  Open Access Emerg Med       Date:  2010-03-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.